LQDA (Pharmaceuticals) Stock Valuation & Fair Value Fairly valued
LQDA (Pharmaceuticals) trades at a blended P/E of 51.7, in line with its historical valuation, with a forward growth estimate of 75.8% and a PEG of 0.68. Analysts' one-year estimates have been hit 14% of the time.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is LQDA overvalued?
At a blended P/E of 51.7, LQDA is broadly in line with its historical valuation, with a PEG of 0.68 on 75.8% forward growth. tickerseer currently rates it fairly valued.
What is LQDA's fair value and PEG?
LQDA trades at a blended P/E of 51.7, a PEG of 0.68, and a forward growth estimate of 75.8%.
Has tickerseer's rating of LQDA changed?
tickerseer's rating has been fairly valued since 2026-07-31.
Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.